BCMAS EXAM AND STUDY GUIDE NEWEST 2026 TEST
BANK| COMPLETE 650 REAL EXAM QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+| BCMAS FINAL EXAM PREP
2026 (BRAND NEW!!)
1. What is the primary purpose of an Investigational New
Drug (IND) application?
A. To market a new drug
B. To obtain permission to ship an investigational drug across
state lines for clinical trials
C. To report adverse events to the FDA
D. To renew a drug patent
Answer: B – To obtain permission to ship an investigational
drug across state lines for clinical trials
Rationale: An IND is filed with the FDA to obtain an exemption
from the Federal Food, Drug, and Cosmetic Act, allowing the
1
,sponsor to lawfully ship an investigational drug for human use in
clinical trials.
2. Which phase of a clinical trial primarily assesses safety and
tolerability in a small number of healthy volunteers or
patients (20–80 subjects)?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: A – Phase I
Rationale: Phase I trials are first-in-human studies focused on
safety, tolerability, pharmacokinetics, and pharmacodynamics.
Phase II assesses efficacy and dose-ranging; Phase III is large-scale
confirmatory efficacy; Phase IV is post-marketing surveillance.
3. What does “IND” stand for in drug development?
A. Investigational New Drug
2
,B. International New Drug
C. Investigational Nonclinical Drug
D. Immediate New Drug
Answer: A – Investigational New Drug
Rationale: The IND application is the mechanism by which a sponsor
obtains FDA authorization to begin human clinical trials after
completing preclinical studies.
4. Which type of FDA application is submitted for approval to
market a new drug in the United States?
A. IND
B. ANDA
C. NDA (New Drug Application) or BLA (Biologics License
Application)
D. IDE
Answer: C – NDA (New Drug Application) or BLA (Biologics
License Application)
3
, Rationale: An NDA is for small molecule drugs; a BLA is for
biologics (monoclonal antibodies, gene therapies, etc.). Both
request FDA approval for marketing.
5. An Abbreviated New Drug Application (ANDA) is used for:
A. New molecular entities
B. Generic drugs that are bioequivalent to a reference listed
drug
C. Biologics
D. Over-the-counter (OTC) monograph products
Answer: B – Generic drugs that are bioequivalent to a
reference listed drug
Rationale: The ANDA pathway allows generic drug approval
without repeating clinical trials, provided bioequivalence is
demonstrated and no new patents/ exclusivities block entry.
6. The “PHS Act” section 351(a) and (k) apply to:
A. Small molecules
4
BANK| COMPLETE 650 REAL EXAM QUESTIONS AND
CORRECT DETAILED ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+| BCMAS FINAL EXAM PREP
2026 (BRAND NEW!!)
1. What is the primary purpose of an Investigational New
Drug (IND) application?
A. To market a new drug
B. To obtain permission to ship an investigational drug across
state lines for clinical trials
C. To report adverse events to the FDA
D. To renew a drug patent
Answer: B – To obtain permission to ship an investigational
drug across state lines for clinical trials
Rationale: An IND is filed with the FDA to obtain an exemption
from the Federal Food, Drug, and Cosmetic Act, allowing the
1
,sponsor to lawfully ship an investigational drug for human use in
clinical trials.
2. Which phase of a clinical trial primarily assesses safety and
tolerability in a small number of healthy volunteers or
patients (20–80 subjects)?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: A – Phase I
Rationale: Phase I trials are first-in-human studies focused on
safety, tolerability, pharmacokinetics, and pharmacodynamics.
Phase II assesses efficacy and dose-ranging; Phase III is large-scale
confirmatory efficacy; Phase IV is post-marketing surveillance.
3. What does “IND” stand for in drug development?
A. Investigational New Drug
2
,B. International New Drug
C. Investigational Nonclinical Drug
D. Immediate New Drug
Answer: A – Investigational New Drug
Rationale: The IND application is the mechanism by which a sponsor
obtains FDA authorization to begin human clinical trials after
completing preclinical studies.
4. Which type of FDA application is submitted for approval to
market a new drug in the United States?
A. IND
B. ANDA
C. NDA (New Drug Application) or BLA (Biologics License
Application)
D. IDE
Answer: C – NDA (New Drug Application) or BLA (Biologics
License Application)
3
, Rationale: An NDA is for small molecule drugs; a BLA is for
biologics (monoclonal antibodies, gene therapies, etc.). Both
request FDA approval for marketing.
5. An Abbreviated New Drug Application (ANDA) is used for:
A. New molecular entities
B. Generic drugs that are bioequivalent to a reference listed
drug
C. Biologics
D. Over-the-counter (OTC) monograph products
Answer: B – Generic drugs that are bioequivalent to a
reference listed drug
Rationale: The ANDA pathway allows generic drug approval
without repeating clinical trials, provided bioequivalence is
demonstrated and no new patents/ exclusivities block entry.
6. The “PHS Act” section 351(a) and (k) apply to:
A. Small molecules
4
